The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Recruiting

Phase 1

Phase 2

Cyclophosphamide, Sirolimus, Mycophenolate MofetilThe Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Sponsor:

National Cancer Institute (NCI)

Code:

NCT05436418

Conditions

Peripheral Blood Stem Cell Transplantation

Hematopoietic Stem Cell Transplantation

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Accepted

Interventions

Melphalan

Sirolimus

Total Body Irradiation (TBI)

Cyclophosphamide

Mycophenolate Mofeti

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-10. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-06-17.